Heron Therapeutics

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Heron Therapeutics, Inc., formerly Calando Pharmaceuticals, Inc., was incorporated in November 2004 and started operations in October 2005. It is a biotechnology company focused on developing pharmaceutical products to address unmet medical needs. The Company’s programs base on using its proprietary Cobalamin, Polymerized-IFN alpha and Biochronomer drug delivery technologies to create improved therapeutic profiles. It is focused on developing innovative and differentiated product candidates that address major unmet needs in pain management and cancer.

At Heron, we strive to meet the unmet medical needs of patients living with cancer and beyond. We are dedicated to developing novel, science-driven solutions that address critical needs in pain management, using our innovative Biochronomer drug delivery technology as a platform.

We seek to provide solutions to problems that have not been adequately addressed in the past. Heron is committed to improving lives by developing innovative therapies that deliver improved patient outcomes.

Heron Therapeutics

Share

Contacts

Follow Us

Heron Therapeutics

Share

Contacts

Follow Us